MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'copaxone'. Sat, 03 Sep 2011 03:01:29 +0100 http://www.medworm.com/index.php?rid=5086560&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FfEJZC4F4xVU%2F Good morning, everyone. Hope you had a nice weekend. Now, of course, the routine resumes, although this is often a slow time of year. Nonetheless, there is much to be done here in the official Pharmalot c-suite, where we are catching up on interesting documents and conversations. And of course, we are brewing that mandatory cup of stimulation and invite you to join us. Meanwhile, here are a few tidbits from around the world. Hope your day goes well and you accomplish much… Teva’s Copaxone Successor Fails In Latest Clinical Trial (Bloomberg News) Pfizer Says FDA Delays Prevnar Review For Three Months (Bloomberg News) Cuba Sentences Pharma Execs For Corruption (Associated Press) Japan’s Shionogi Acquires C&O Pharmaceutical Tech (ChannelNewsAsia) New FDA Commish Asks Co... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5086560 Mon, 01 Aug 2011 12:00:25 +0100 5086560 http://www.medworm.com/index.php?rid=4622506&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FN2UKxcXoMyU%2F What goes up….will keep going up? Ever since Novartis introduced the first pill to treat multiple sclerosis last year, prices for MS meds have jumped as much as 39 percent. Why? Other drugmakers are charging more for their older treatments in order to maintain revenue in the face of eroding unit sales, Bloomberg News writes. Novartis charges $48,000 for its new Gilenya pill, which prompted Teva Pharmaceutical to raise the price of its Copaxone injectable by 39 percent to $42,300 a year since January 2010. And the cost of MS drugs, which patients generally take for life, is now on par with many cancer meds. Consequently, patients without insurance or who do not qualify for assistance programs may be out of luck. Biogen’s Tysabri costs about $3,566 a month, or $42,788 a year, while... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4622506 Tue, 22 Mar 2011 12:28:26 +0100 4622506 http://www.medworm.com/index.php?rid=4560597&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FC7Wu-i1zM6o%2F Hello, everyone, and top of the morning to you. Another shiny day is unfolding here on the Pharmalot corporate campus, where we are hustling the short people off to their various school houses for some learning. And this marathon calls for a much needed cup of stimulation - our flavor today is Cinnamon Cream Swirl. Please join us as we also peruse the news for interesting developments. As always, we encourage you to contact us if you hear of something noteworthy. Meanwhile, have a great day… FDA Warns About Abbott HIV Med In Premature Babies (Reuters) Teva Says Docs Contacted For Generic Copaxone Study (Bloomberg News) FDA Accepts Application For Astra & Bristol Diabetes Drug (Associated Press) Japan Finds No Direct Link To Vaccines And Deaths (Reuters) FTC Takes Aim At Patent T... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4560597 Tue, 08 Mar 2011 12:53:17 +0100 4560597 http://www.medworm.com/index.php?rid=4152267&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FhA34mJ2aYlk%2F Two months ago, the FDA approved a new type of drug from Novartis called Gilenya to treat relapsing forms of multiple sclerosis and delay the progression of physical disabilities. MS, of course, is hard to treat and since Gilenya is a once-daily pill, the betting is that Novartis has a blockbuster on its hands (back story). But how big? A survey of 43 MS specialists by Leerink Swann finds that Gilenya may grab 13 percent of the US market within one year and 19 percent in two years. If this comes true, Gilenya’s market share by then would exceed all of the competition - Biogen’s Avonex with 18 percent market share; EMD Serono and Pfizer’s Rebif at 15 percent; Bayer’s Betaseron with 9 percent and Biogen’s Tysabri at 8 percent. Only Teva’s Copaxone would be... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4152267 Wed, 10 Nov 2010 16:46:41 +0100 4152267 http://www.medworm.com/index.php?rid=4105666&cid=t_192221_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fis-looking-at-long-term-impossible-in-our-healthcare-system%2F2010.10.25 I spent last week in Gothenburg, Sweden covering the European Committee for the Treatment of Multiple Sclerosis (ECTRIMS) meeting. Lots of good science, lots of excitement over the new oral and targeted therapies coming on the market to treat this awful disease. But what I want to write about isn’t the science, but about how it will play out in the brave new world of healthcare in which we all live in today. For instance, consider the first oral therapy to hit the market: Gilenya (fingolimod), which the FDA approved in September. Last month Novartis announced the price: $48,000 a year. This is not a rant against the high cost of drugs, however. It is a rant against the inability of our healthcare system to take the long view of the impact of such drugs, a view that is particularly im... Better Health blogs http://www.medworm.com/rss/comments.php?id=4105666 Mon, 25 Oct 2010 20:00:00 +0100 4105666 http://www.medworm.com/index.php?rid=3564202&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fp-W5nW88_Ek%2F And so another working week will soon draw to a close. Already, we foresee brisk walks with the official Pharmalot mascot and cozy naps on the official Pharmalot couch. What will you do this weekend? Before getting carried away, there are those meetings and deadlines to conquer. So please join us as we quaffe a cup of stimulation and prepare for the day. And have a great weekend, whatever you do. See you soon… Pfizer And Strides Sign Deal For Oncology Drugs (Reuters) FDA Rejects Teva Petition To Block Generic Copaxone (Globes Online) How Valuable Is Arena’s Fat Pill? (Seeking Alpha) Diet Pills Are Bought Too Easily In The UK (BBC Watchdog) Florida May Tighten Psychotropic Drug Rules (Daytona Beach News-Journal) photo thx to tipiro on Flickr creative commons (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3564202 Fri, 14 May 2010 12:04:38 +0100 3564202 http://www.medworm.com/index.php?rid=3052389&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FyhmgcKLriZ8%2F A program designed by the government to require a money-back guarantee on drugmakers if their meds didn’t adequately treat patients has failed to provide any evidence that it was cost effective, The Financial Times reports. The plan was launched more than seven years ago. The study of five multiple sclerosis drug is the first public analysis of a “risk-sharing” program established by the UK’s Department of Health and several drugmakers after the National Institute for Health and Clinical Excellence, or NICE, advised the National Health Service not to use the meds. The findings, which were published in the British Medical Journal (see here) raise questions about the growing number of other such programs between drugmakers and the UK government, the FT writes. The results als... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3052389 Thu, 03 Dec 2009 13:44:05 +0100 3052389 http://www.medworm.com/index.php?rid=3044889&cid=t_192221_129_f&fid=36038&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Ftrevis-life-with-multiple-sclerosis-ms%2Fhalt-ms-and-stem-cell-research%2F My wife, Caryn and I were talking the other day about my next options for MS disease modifying therapies. As many of you know, interferon treatments are out for me.  Copaxone is prohibitively expensive (and because of Medicare Part B, I am not eligible for drug company assistance) and I’ve used my lifetime maximum of Novantrone.  That would seem to leave Tysabri as our only (FDA approved) option. Then we started talking about the HALT-MS (high-dose immunosuppression and autologous stem cell transplantation for MS) study as a possible option.  HALT-MS is an experimental treatment for multiple sclerosis which is showing some very impressive results. The problem is…well the problems are many.  The first problem was that I didn’t know as much about the treatment as I should! I ma... Life with MS blogs http://www.medworm.com/rss/comments.php?id=3044889 Mon, 30 Nov 2009 22:40:07 +0100 3044889 http://www.medworm.com/index.php?rid=1616436&cid=t_192221_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F332676961%2F The Israeli Ministry of Health and the Public Complaints Commissioner have appointed a special committee to study how Teva Pharmaceutical conducted a trial of its Copaxone multiple sclerosis drug, according to Globes. According to a report submitted by Proneuron Biotechnologies, Teva allegedly tested Copaxone on ALS patients, despite knowing that previous trials on mice with ALD raised doubts about its safety. As early as six months ago, the Ministry of Health comptroller began investigating the conduct of the Health Ministry, which approved the trials, and the Tel Aviv Sourasky Medical Center, where the trials were conducted in conjunction with similar trials in five other countries, the paper writes. The investigation revealed that the Ministry of Health pharmacology division didn’... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1616436 Fri, 11 Jul 2008 13:13:15 +0100 1616436